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Abstract
IMPORTANCE—The use of anticholinergic (AC) medication is linked to cognitive impairment 
and an increased risk of dementia. To our knowledge, this is the first study to investigate the 
association between AC medication use and neuroimaging biomarkers of brain metabolism and 
atrophy as a proxy for understanding the underlying biology of the clinical effects of AC 
medications.
OBJECTIVE—To assess the association between AC medication use and cognition, glucose 
metabolism, and brain atrophy in cognitively normal older adults from the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) and the Indiana Memory and Aging Study (IMAS).
DESIGN, SETTING, AND PARTICIPANTS—The ADNI and IMAS are longitudinal studies 
with cognitive, neuroimaging, and other data collected at regular intervals in clinical and academic 
research settings. For the participants in the ADNI, visits are repeated 3, 6, and 12 months after the 
baseline visit and then annually. For the participants in the IMAS, visits are repeated every 18 
months after the baseline visit (402 cognitively normal older adults in the ADNI and 49 
cognitively normal older adults in the IMAS were included in the present analysis). Participants 
were either taking (hereafter referred to as the AC+ participants [52 from the ADNI and 8 from the 
IMAS]) or not taking (hereafter referred to as the AC− participants [350 from the ADNI and 41 
from the IMAS]) at least 1 medication with medium or high AC activity. Data analysis for this 
study was performed in November 2015.
MAIN OUTCOMES AND MEASURES—Cognitive scores, mean fludeoxyglucose F 18 
standardized uptake value ratio (participants from the ADNI only), and brain atrophy measures 
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from structural magnetic resonance imaging were compared between AC+ participants and AC− 
participants after adjusting for potential confounders. The total AC burden score was calculated 
and was related to target measures. The association of AC use and longitudinal clinical decline 
(mean [SD] follow-up period, 32.1 [24.7] months [range, 6–108 months]) was examined using 
Cox regression.
RESULTS—The 52 AC+ participants (mean [SD] age, 73.3 [6.6] years) from the ADNI showed 
lower mean scores on Weschler Memory Scale–Revised Logical Memory Immediate Recall (raw 
mean scores: 13.27 for AC+ participants and 14.16 for AC− participants; P = .04) and the Trail 
Making Test Part B (raw mean scores: 97.85 seconds for AC+ participants and 82.61 seconds for 
AC− participants; P = .04) and a lower executive function composite score (raw mean scores: 0.58 
for AC+ participants and 0.78 for AC− participants; P = .04) than the 350 AC− participants (mean 
[SD] age, 73.3 [5.8] years) from the ADNI. Reduced total cortical volume and temporal lobe 
cortical thickness and greater lateral ventricle and inferior lateral ventricle volumes were seen in 
the AC+ participants relative to the AC− participants.
CONCLUSIONS AND RELEVANCE—The use of AC medication was associated with 
increased brain atrophy and dysfunction and clinical decline. Thus, use of AC medication among 
older adults should likely be discouraged if alternative therapies are available.
Anticholinergic (AC) medications have been linked to impaired cognition1–16 primarily in 
nondemented older adults10,17 and an increased risk for cognitive impairment and dementia 
in older adults.1,3,4,18–20 The biological basis for the cognitive effects of AC medications is 
unknown. However, given the importance of the cholinergic system in cognition, researchers 
speculate that direct impairment of cholinergic neurons may underlie these effects. In fact, 
previous studies21,22 using scopolamine hydrobromide, a cholinergic antagonist, have shown 
transient cognitive impairment in young and older adults. A recent study23 suggested that 
administration of AC medications modulates the association between brain volume and 
cognition. However, to our knowledge, no studies have examined the effects of regular AC 
medication use on neuroimaging measures of brain structure and function in cognitively 
normal (CN) older adults.
The goal of the present study was to assess AC medication use in CN older adults from the 
Alzheimer’s Disease Neuroimaging Initiative (ADNI). In particular, we sought to evaluate 
whether cognitive performance, brain glucose hypometabolism, structural brain atrophy, and 
clinical progression to mild cognitive impairment (MCI) and/or Alzheimer disease (AD) 
were associated with the use of AC medication. We also completed a similar analysis in an 
independent cohort of CN older adults from the Indiana Memory and Aging Study(IMAS). 
We hypothesized that participants taking AC medications (hereafter referred to as AC+ 
participants) would show poorer cognition, reduced glucose metabolism, brain atrophy, and 
increased clinical decline relative to those not taking AC medications (hereafter referred to 
as AC− participants) and that these effects would be greatest in those with the highest total 
AC burden score.
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Methods
Alzheimer’sDisease Neuroimaging Initiative
Data used in the preparation of this article were obtained from the ADNI (http://
adni.loni.usc.edu; for more information, see the eAppendix in the Supplement,http://
www.adni-info.org, and previous reports24–29). Written informed consent was obtained 
according to the Declaration of Helsinki.30
Indiana Memory and Aging Study
The IMAS includes CN participants, participants with subjective cognitive decline, 
participants with MCI, and participants with AD, but only data from CN participants and 
participants with subjective cognitive decline were used for this analysis. Participants 
provided written informed consent according to the Declaration of Helsinki,30 and the 
procedures were approved by the Indiana University Committee for the Protection of Human 
Subjects.
AC Medications
Medication logs from the ADNI and the IMAS were manually curated to identify 
medications with low, medium, or high AC effects as defined by the Anticholinergic 
Cognitive Burden (ACB) scale and other reports.18,31–33 See eTable 1 in the Supplement for 
all medications identified. To be defined as an AC+ participant, participants had to have been 
taking the medication at the baseline visit for a minimum of 1 month. The total AC burden 
score was also calculated using the ACB scale, which uses the literature to guide an expert-
based determination of the adverse cognitive AC activities (low effect = 1, medium effect = 
2, and high effect = 3). The total AC burden score was the sum of ACB scores of all 
applicable medications taken by a participant.4,6,8 See eTable 2 in the Supplement for 
medications included in calculating the total AC burden score.
Participants
A total of 402 CN participants from ADNI 1, ADNI Grand Opportunity, and ADNI 2, 
including 301 CN participants without significant memory concerns and 101 CN 
participants with significant memory concerns, were included in the present analysis. A 
diagnosis was made as previously described34,35 and as in the ADNI 2 manual (http://
www.adni-info.org/Scientists/doc/ADNI2_Procedures_Manual_20130624.pdf). Participants 
were divided by AC medication use into those taking 1 or more medications with medium or 
high AC activity (AC+ participants) and those not taking any such medications (AC− 
participants), resulting in 52 AC+ participants and 350 AC− participants. There was no 
significant difference in the rates of AC use between CN participants with significant 
memory concerns and those without, nor was there a significant effect of diagnosis (with or 
without significant memory concerns) or of the interaction between diagnosis and AC use on 
clinical progression.
The CN participants with or without subjective cognitive decline from the IMAS were also 
evaluated as an independent replication sample. Participants were CN if they had normal 
cognition relative to demographically adjusted norms and no significant self- or informant-
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based cognitive complaints. Participants had subjective cognitive decline if they had normal 
cognition and self- and/or informant-based complaints. From the IMAS, there were 8 AC+ 
participants and 41 AC− participants.
Cognitive Testing
The ADNI participants underwent a comprehensive cognitive and clinical battery. We 
assessed the effect of AC use on executive function (Trail Making Test Part B [TMT-B], a 
composite executive function score36) and memory (Weschler Memory Scale–Revised 
Logical Memory Immediate and Delayed, a composite memory score37).
Participants from the IMAS received a battery of neuropsychological tests and cognitive 
concern questionnaires, most of which have been previously described.38 After pread-justing 
for age, sex, and education, combined z scores (relative to the complete IMAS CN group) 
were generated for 3 domains: executive function, memory, and general cognition. We then 
assessed the effect of AC use on the z scores of these 3 domains.
Fluorodeoxyglucose F 18 Positron Emission Tomography
Preprocessed fluorodeoxyglucose F 18–positron emission tomographic (FDG-PET) scans 
(coregistered, averaged, standardized image and voxel size, and uniform resolution) were 
downloaded from the ADNI Laboratory of Neuroimaging (LONI) site (http://
adni.loni.usc.edu) and processed as previously described.25,34 Mean standardized uptake 
value ratios (SUVRs) were extracted from 2 regions of interest, including a bilateral 
hippocampal region of interest39 and an overall cortical region of interest representing 
regions where CN participants show greater glucose metabolism than participants with AD 
from the full ADNI 1 cohort. Seventy-three participants were excluded from FDG-PET 
analyses for missing data. The IMAS participants did not undergo FDG PET.
Structural Magnetic Resonance Imaging
Baseline structural 3-T magnetic resonance imaging (MRI) scans were downloaded from 
LONI for ADNI 2 participants; ADNI 1 participants were excluded because their scans were 
collected on 1.5-T scanners using a different protocol. Scans were corrected prior to 
downloading as previously described.24 After downloading, we processed the scans using 
FreeSurfer version 5.134,35 to extract target measures of atrophy selected for known 
relevance in cognitive function and AD (temporal lobe, ventricle volume, and total cortex). 
If 2 MRI scans were available, the values from both scans were averaged. A total of 116 
ADNI participants were excluded from this analysis owing to missing data. The IMAS 
participants underwent structural magnetization-prepared rapid acquisition gradient-echo 
scans on a Siemens 3T Tim Trio using the ADNI sequence. Similar to ADNI, scans were 
processed using FreeSurfer version 5.1 to extract the same atrophy measures. Two 
participants were excluded owing to missing data.
Confounding Effects of Medical History and Medication Use
Because the observed effects may potentially be caused by overall morbidity in AC+ 
participants, we evaluated the effect of the total number of medications, the total number of 
common comorbid conditions, and the presence or absence of each comorbid condition. The 
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comorbid conditions tested included transient ischemic attack, myocardial infarction, cardiac 
surgery, hypertension, hyperlipidemia, diabetes, sleep apnea, other vascular disorders, 
insomnia, depression, anxiety, attention-deficit/hyperactivity disorder, and other psychiatric 
disorders. First, we determined whether there was a difference between AC+ participants and 
AC− participants regarding medical history and medication use (Table). Next, we determined 
whether these variables were associated with the outcome variables. Finally, we included 
those variables that were either different between AC+ participants and AC− participants or 
associated with an outcome in the general linear model assessing the effect of AC 
medication use on cognitive and imaging measures. Only those that were significant within 
the final general linear model were included (covariates reported in the Results). 
Furthermore, we randomly selected samples matched on medical history variables (52 AC− 
participants and 52 AC+ participants) and ran similar analyses.
Statistical Analysis
In the ADNI, cross-sectional measures of cognitive performance, glucose metabolism, and 
brain atrophy were compared between AC+ participants and AC− participants using a 
general linear model preadjusted for age, sex, and Aβ positivity (yes/no; defined using 
previously established cutoffs on either cerebrospinal fluid sample [Aβ1–42 < 192 mg/
mL]40 or cortical florbetapir F-18 SUVR [SUVR≥1.1],41 years of education [included in 
analyses of cognitive variables only], and total intracranial volume [included in analyses of 
MRI variables only] using the residuals of a linear regression model). After checking 
normality, we determined that the TMT-B score, the FDG SUVR in the cortical region of 
interest, and the inferior lateral ventricle and lateral ventricle volumes were skewed. Using 
log transformations, we normalized the TMT-B scores and FDG SUVR in the overall 
cortical region-of-interest variables, while the ventricular volumes were normalized using a 
square root transformation. These transformed variables were used in the statistical analyses 
to test the effect of AC medication use. All other variables were normally distributed, so 
untransformed values are reported. The statistical threshold for significance was set at P < .
05.
Associations between the total AC burden score and cognitive performance, glucose 
metabolism, and brain atrophy measures were evaluated using Spearman correlation models. 
Target cognitive and imaging variables were preadjusted for age, sex, Aβ positivity, 
education, medical history variables (see Results), and total intracranial volume as 
appropriate.
Finally, a Cox regression model was used to determine whether AC medication use was 
associated with clinical progression from CN to MCI and/or AD in the ADNI cohort (mean 
[SD] follow-up period, 32.1 [24.7] months [range, 6–108 months]), covaried for age, sex, 
medical history variables (see Results), and Aβ positivity. We also looked at the interaction 
of AC medication use and Aβ positivity on clinical progression.
Cognitive performance and brain atrophy measures were compared between AC+ 
participants and AC− participants in the IMAS to replicate the results observed in the ADNI. 
All measures showed a normal distribution. A general linear model was used to assess the 
effect of AC medication use in the IMAS, co-varied for age, sex, education, and total 
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intracranial volume as appropriate. Associations between the total AC burden score and 
cognitive performance and brain atrophy measures were also evaluated using Spearman 
correlation models. No medical history variables were found to be significant covariates in 
the IMAS.
Results
Cognitive Performance
No significant differences in age, sex, education, ethnicity/ race, or APOE ε4 genotype were 
observed between AC+ participants and AC− participants in either sample (Table; see eTable 
3 in the Supplement for the demographic characteristics of the IMAS participants). Of the 
medical variables examined, only the total number of medications, the total number of 
comorbid conditions, anxiety, and depression were different between AC+ participants and 
AC− participants (P < .05). Significant effects of AC medication use on the mean Logical 
Memory–Immediate score (raw mean scores: 13.27 for AC+ participants and 14.16 for AC− 
participants; P = .04 [Figure 1A]), the mean TMT-B score (raw mean scores: 97.85 seconds 
for AC+ participants and 82.61 seconds for AC− participants; P = .04 [Figure 1B], with 
transient is-chemic attack as an additional covariate), and the mean composite executive 
function score (raw mean scores: 0.58 for AC+ participants and 0.78 for AC− participants; P 
= .04 [Figure 1C], with transient ischemic attack, myocardial infarction, and diabetes as 
additional covariates) were found, with AC+ participants showing lower scores than AC− 
participants. The mean Logical Memory–Delayed Memory score (raw mean scores: 12.40 
for AC+ participants and 13.24 for AC− participants; P = .07) and the mean memory 
composite score (raw mean scores: 0.85 for AC+ participants and 0.93 for AC− participants; 
P = .11 [data not shown]) trended toward significance, with AC+ participants showing lower 
scores than AC− participants. In the IMAS, the general mean cognition z score was 
significantly reduced for the AC+ participants relative to the AC− participants (raw mean 
scores: −1.27 for AC+ participants and −0.34 for AC− participants; P = .03 [eFigure 1 in the 
Supplement]).
FDG Positron Emission Tomography
Differences in glucose metabolism between AC+ participants and AC− participants were 
observed, with the AC+ participants showing reduced glucose metabolism in the 
hippocampus (raw mean values: 1.06 for the AC+ participants and 1.08 for AC− participants; 
P = .02 [Figure 1D], with anxiety as an additional covariate) and the global FDG-PET region 
of interest (raw mean values: 1.48 for AC+ participants and 1.52 for AC− participants; P = .
03 [Figure 1E], with concussion and other vascular diseases as additional covariates) relative 
to AC− participants.
Structural MRI
A significant effect of AC medication use on brain structure was also observed. The AC+ 
participants demonstrated reduced total cortical volume (raw mean values: 406134.21 mm3 
for AC+ participants and 423107.01 mm3 for AC− participants; P = .02 [Figure 2A]) and 
larger lateral ventricle (raw mean values: 17880.19 mm3 for AC+ participants and 15620.22 
mm3 for AC− participants; P = .01 [Figure 2B]) and inferior lateral ventricle volumes (raw 
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mean values: 757.25 mm3 for A C+ participants and 571.49 mm3 for AC− participants; P < .
001 [Figure 2C]) relative to the AC− participants. Regional effects were also observed in the 
temporal lobe, with AC+ participants showing a reduced temporal lobe cortical thickness 
(raw mean values: 2.80 mm for AC+ participants and 2.84 mm for AC− participants; P = .02 
[Figure 2D], with concussion as an additional covariate) and a reduced medial temporal lobe 
(MTL) cortical thickness (raw mean values: 3.10 mm for AC+ participants and 3.15 mm for 
AC− participants; P = .02 [Figure 2E], with concussion and cardiac surgery as additional 
covariates) relative to AC− participants. In the IMAS, the AC+ participants had a reduced 
MTL cortical thickness (raw mean values: 2.91 mm for AC+ participants and 3.10 mm for 
AC− participants; P = .01 [eFigure 2A in the Supplement]) and showed a trend toward 
thinner bilateral temporal lobe cortices (raw mean values: 2.69 mm for AC+ participants and 
2.81 mm for AC− participants; P = .05 [eFigure 2B in the Supplement]) compared with the 
AC− participants.
Association of Total AC Burden Score With Cognition and Brain Atrophy
Significant associations of the total AC burden score with cognition and brain atrophy were 
observed. Specifically, a higher total AC burden score was associated with a poorer TMT-B 
performance (r = 0.137; P = .01 [Figure 3A], with transient ischemic attack and total number 
of medications additional as co-variates) and greater inferior lateral ventricle (r = 0.126; P 
= .03 [Figure 3B]) and lateral ventricle volumes (r = 0.154; P = .01 [Figure 3C]). The 
inferior lateral ventricle volume remained significantly associated with the total AC burden 
score after excluding participants with a total AC burden score of 0 (r = 0.331; P < .001 
[Figure 3E]). The TMT-B score (r = 0.146; P = .06 [Figure 3D]) and the lateral ventricle 
volume (r = 0.152; P = .10 [Figure 3F]) showed nonsignificant trend associations with the 
total AC burden score after excluding those participants with a total AC burden score of 0.
In the IMAS, the pattern of results was similar, although mostly nonsignificant trends were 
observed owing to attenuated power. Specifically, a higher total AC burden score was 
associated with reduced general cognition and atrophy (eFigure 3 in the Supplement). A 
trend for a negative association between the total AC burden score and general cognition 
across all participants (r = −0.239; P = .10 [eFigure 3A in the Supplement]) was observed, 
which was significant after excluding those with a total AC burden score of 0 (r = −0.625; P 
= .004 [eFigure 3C in the Supplement]). A negative association was observed between the 
total AC burden score and MTL cortical thickness (r = −0.313; P = .03 [eFigure 3B in the 
Supplement]), which only trended toward significant after excluding those with a total AC 
burden score of 0 (r = −0.428; P = .07 [eFigure 3D in the Supplement]).
Association of AC Use With Future Progression
A significant association between AC medication use and future progression of ADNI 
participants to MCI and/or AD was observed (P = .01; hazard ratio, 2.47 [Figure 4A]; with 
total number of medications, cardiac surgery, total number of comorbid conditions, and 
other psychiatric conditions as additional covariates). After evaluating the interaction 
between AC medication use and Aβ positivity, we observed that AC+ participants who are 
Aβ positive showed the highest risk of conversion relative to AC− participants who are Aβ 
negative (P < .001; hazard ratio, 7.73 [Figure 4B]; with cardiac surgery and other psychiatric 
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conditions as additional covariates) or those who are positive for either AC medication use 
or Aβ (P = .001; hazard ratio, 4.24 [Figure 4B]).
Matched Sample
In the matched sample, the AC+ participants showed reduced total cortex volumes (raw 
mean values: 406134.21 mm3 for AC+ participants and 417770.60 mm3 for AC− 
participants; P = .01), increased inferior lateral ventricle volumes (raw mean values: 757.25 
mm3 for AC+ participants and 583.62 mm3 for AC− participants; P = .02), and an increased 
likelihood for clinical conversion (P = .01; hazard ratio, 3.87 [data not shown]) compared 
with the AC− participants. The AC+ participants also showed a trend toward poorer Logical 
Memory–Immediate performance (raw mean values: 13.27 for AC+ participants and 14.42 
for AC− participants; P = .08) and increased lateral ventricle volumes (raw mean values: 
17880.19 mm3 for AC+ participants and 15164.28 mm3 for AC− participants; P = .10 [data 
not shown]) compared with the AC− participants.
Discussion
Use of medications with medium or high AC effects in the ADNI cohort was associated with 
poorer cognition (particularly in immediate memory recall and executive function), reduced 
glucose metabolism, whole-brain and temporal lobe atrophy, and clinical decline. The effect 
appeared additive because an increased burden of AC medications was associated with 
poorer executive function and increased brain atrophy. Similar effects were seen in an 
independent cohort of older adults. These results suggest that medications with AC 
properties may be detrimental to brain structure and function, as well as cognition.
The observed findings support previous reports1–16 regarding the association between AC 
medication use and cognitive impairments, with a significant effect of AC medication use on 
executive and immediate, rather than delayed, memory. We also found that the increased 
clinical progression from CN to MCI and/or AD was associated with AC medication use.
This study is one of the first, to our knowledge, to examine in vivo brain structural and 
functional differences between CN participants taking medications with medium or high AC 
activity and CN participants not taking these medications. We observed that AC+ 
participants had reduced brain glucose metabolism and increased brain atrophy compared 
with AC− participants. Furthermore, those with the highest total AC burden scores showed 
the most atrophy.
The increased brain atrophy and decreased brain function that we observed may be linked to 
the central effects of AC medications on cholinergic pathways within the brain. Cholinergic 
pathways, especially those extending from the basal fore-brain, are important for 
cognition.42 Studies have suggested that AC medications may affect cognition by altering 
cholinergic inputs, with a study23 showing that AC medication administration leads to an 
uncoupling between brain structure and cognition in older adults. The process by which AC 
medications might lead to neurodegeneration is less clear. Cholinergic receptor antagonists 
have been shown to induce cell death,43 while increased cholinergic neurotransmission 
reduces neurodegeneration in an AD mouse model.44 Decreased cholinergic activity due to 
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AC medications may induce synaptic loss and neurodegeneration in regions with significant 
cholinergic innervation, namely the MTL and cortex.45
In mice, lesioning or damaging cholinergic neurons in the basal forebrain has been shown to 
cause degeneration of the septal-hippocampal and basalo-cortical projections and neurons in 
the hippocampus and cortex.46 Another possibility is that participants taking AC 
medications may be more sensitive to neuronal damage in response to stress. This 
hypothesis centers around the interaction of cholinergic systems and stress because MTL 
cholinergic neurons have been shown to regulate the hypothalamic-pituitary-adrenal axis.47 
Reduced cholinergic activity has been linked to increased plasma corticosterone levels, 
which in turn are linked to increased hippocampal cell death.47 Furthermore, chronic stress 
has been associated with increased Aβ levels, tau hyperphosphorylation and aggregation, 
and neurodegeneration in mouse models through dysregulation of the hypothalamic-
pituitary-adrenal axis.48
Overall, the findings in this study provide a potential biological basis for the reduced 
cognition associated with the use AC medications through the functional and structural 
changes in the brain. However, future longitudinal studies with imaging and other brain 
biomarkers, as well as in animal models, are needed to more fully understand the 
mechanism underlying the effect of AC medications on the brain.
There are a few notable limitations to this study. First, the information on medication use 
was based on self-report rather than directly ascertained through medical/prescription 
records. Self-report could be inaccurate because participants may forget to report specific 
medication use. However, given the normal cognitive status of the participants at baseline, it 
is unlikely that they would have reported taking medications that they were, in fact, not 
taking. Thus, the observed effect is potentially underestimated because some AC− 
participants may in fact have been taking an AC medication. Future studies using medical/ 
pharmacy records, along with imaging and biomarker measures, would help to confirm the 
findings of the present study.
A second limitation is the relatively small sample size of AC+ participants. Future studies 
using larger samples are warranted. A third limitation is the inability to determine the 
causality of the findings because the results may be due to poor health rather than AC 
medication use.49 We did include common comorbid health conditions (eg, vascular and 
psychiatric conditions), total number of medications, and total number of comorbid 
conditions as covariates. However, the only way to determine true causality would be by use 
of a well-controlled prospective longitudinal study.
Another limitation may be the variability in the duration of AC medication use among 
participants. Furthermore, a participant who had taken an AC medication for many years but 
ceased shortly before the baseline visit would not be captured as an AC+ participant. Future 
studies with a better-controlled medication history assessment (ie, using medical/pharmacy 
records and patient self-report) are warranted, as well as studies on the effect of the duration 
of AC medication use on the target outcomes. Finally, only structural MRI and FDGPET 
were assessed in the present report. Future studies examining changes on more advanced 
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imaging measures (ie, diffusion tensor imaging and resting-state or task-based functional 
MRI) would provide additional evidence about the selective effect of AC medications on the 
brain structure and function in specific circuits.
Conclusions
In summary, we observed that CN older adults taking medications with medium or high AC 
activity showed poorer cognition, reduced cerebral glucose metabolism, increased brain 
atrophy, and increased clinical decline compared with those not taking these medications 
and that these symptoms were greatest in CN older adults with the highest total AC burden 
scores. These findings highlight the importance of considering the cognitive adverse effects 
of AC medications before using them to treat older adults at risk for cognitive decline in a 
clinical setting, as well as in therapeutic trials.
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Key Points
Question
Is use of anticholinergic medication associated with poorer cognition, brain 
hypometabolism, brain atrophy, and/or increased risk of clinical decline in cognitively 
normal older adults?
Findings
In this longitudinal study of 2 cohorts of cognitively normal older adults, use of 
medications with medium or high anticholinergic activity was associated with poorer 
memory and executive function, brain hypometabolism, brain atrophy, and increased risk 
of clinical conversion to cognitive impairment. This finding was greatest for those taking 
drugs with the most anticholinergic activity.
Meaning
Use of medication with significant anticholinergic activity should likely be discouraged 
in older adults if alternative therapies are available.
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Figure 1. Association of Anticholinergic (AC) Medication Use With Cognition and Glucose 
Metabolism Among Participants From the Alzheimer’s Disease Neuroimaging Initiative (ADNI)
Cognitively normal older adults taking 1 or more medications with medium or high AC 
activity (referred to as AC+ participants [n = 52]) showed poorer cognition than those not 
taking these medications (referred to as AC− participants [n = 350]), including a lower score 
on the Weschler Memory Scale–Revised Logical Memory Immediate Recall (P = .04 [A]), 
the Trail Making Test Part B (TMT-B) (P = .04 [B]), and an executive function composite (P 
= .04, with transient ischemic attack, myocardial infarction, and diabetes as additional 
covariates [C]). Glucose hypometabolism, as measured by the fluorodeoxyglucose F 18–
positron emission tomographic (FDG-PET) standardized uptake value ratio (SUVR), was 
also observed in the bilateral hippocampus (P = .02, with anxiety as an additional covariate 
[D]) and in a global cortical region of interest of AC+ participants (n = 43) relative to AC− 
participants (n = 286), generated from an analysis of cognitively normal participants who 
show greater glucose metabolism than participants with AD from the full ADNI 1 cohort (P 
= .03, with other vascular conditions and concussion as additional covariates [E]). Error bars 
indicate SD.
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Figure 2. Effect of Anticholinergic (AC) Medication Use on Brain Atrophy Measures
Cognitively normal older adults taking 1 or more medications with medium or high 
anticholinergic activity (referred to as AC+ participants [n = 35]) showed more brain atrophy 
than participants not taking these medications (referred to as AC participants [n = 251]). 
Reduced total cortex volume (P = .02 [A]), increased bilateral lateral ventricle volume (P = .
01 [B]), and increased inferior lateral ventricle volume (P < .001 [C]) were observed in AC+ 
participants relative to AC participants. Furthermore, reduced bilateral temporal lobe (P = .
02, with concussion as an additional covariate [D]) and medial temporal lobe (P = .02, with 
concussion and cardiac surgery as additional covariates [E]) cortical thicknesses were also 
observed. Error bars indicate SD.
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Figure 3. Association of Total Anticholinergic (AC) Burden Score and Brain Atrophy
The total AC burden score was significantly associated with both cognition and brain 
atrophy. Specifically, a higher total AC burden score was associated with poorer 
performance on the Trail Making Test Part B (TMT-B) (r = 0.137; P = .01, with transient 
ischemic attack and total number of medications as additional covariates [A]) and greater 
inferior lateral ventricle (r = 0.126; P = .03 [B]) and lateral ventricle volumes (r = 0.145; P 
= .01 [C]). Inferior lateral ventricle volume was still significantly associated with the total 
AC burden score after excluding participants with a total AC burden score of 0 (r = 0.331; P 
< .001 [E]). The TMT-B score (r = 0.146; P = .06 [D]) and lateral ventricle volume showed 
nonsignificant trend associations with the total AC burden score after excluding those with a 
total AC burden score of 0 (r = 0.152; P = .10 [F]).
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Figure 4. Effect of Anticholinergic (AC) Medication Use on Clinical Conversion
A, A significant association between AC use and future progression of Alzheimer’s Disease 
Neuroimaging Initiative participants to mild cognitive impairment and/or Alzheimer disease 
was observed (P = .01; hazard ratio [HR], 2.47; with total number of medications, cardiac 
surgery, total number of comorbid conditions, and other psychiatric conditions as additional 
covariates).
B, When evaluating the interaction between AC use and Aβ positivity, we found that 
participants taking 1 or more medications with medium or high AC activity who are positive 
for Aβ on florbetapir F-18–positron emission tomographic (PET) scans or cerebrospinal 
fluid (CSF) samples (referred to as AC+ and Aβ+ participants) showed a higher risk of 
conversion relative to participants not taking these medications who are negative for Aβ on 
florbetapir F-18–PET scans or CSF samples (referred to as AC and Aβ participants) (P < .
001; HR, 7.73; with cardiac surgery and other psychiatric conditions as additional 
covariates) and participants who are positive for either AC use or Aβ (P = .001; HR, 4.24).
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Table
Demographic Characteristics and Medical Histories of 402 Participants From the ADNI
Characteristic
Participants, No.
P Value
AC−
(n = 350)
AC+
(n = 52)
Age, mean (SD), y 73.3 (5.8) 73.3 (6.6) .96
Sex
    Male 171 18
.06
    Female 179 34
Education, mean (SD), y 16.4 (2.6) 16.1 (2.7) .40
Handedness
    Right 318 50
.20
    Left 32 2
APOE ε4 positive, % of participants 28.0 25.0 .65
Non-Hispanic white, % of participants 84.6 94.2 .06
Medications, mean (SD), Total No. 4.2 (2.8) 6.7 (3.1) <.001
Comorbid conditions, mean (SD), Total No. 1.8 (1.3) 2.2 (1.5) .03
Transient ischemic attack
    No 341 51
.78
    Yes 9 1
Myocardial infarction
    No 325 51
.15
    Yes 25 1
Cardiac surgery
    No 330 50
.58
    Yes 20 2
Hypertension
    No 193 24
.23
    Yes 157 28
Hyperlipidemia
    No 181 29
.59
    Yes 169 23
Diabetes
    No 324 49
.67
    Yes 26 3
Sleep apnea
    No 334 49
.70
    Yes 16 3
Other vascular conditions (eg, atrial fibrillation)
    No 327 47
.42
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Characteristic
Participants, No.
P Value
AC−
(n = 350)
AC+
(n = 52)
    Yes 23 5
Anxiety
    No 342 47
.01
    Yes 8 5
Depression
    No 306 37
.002
    Yes 44 15
Insomnia
    No 338 46
.01
    Yes 12 6
ADD or ADHD
    No 348 52
.59
    Yes 2 0
Other psychiatric condition (eg, posttraumatic stress disorder)
    No 348 52
.56
    Yes 2 0
Concussion
    No 331 48
.51
    Yes 19 4
Abbreviations: AC+, participant taking anticholinergic medication with medium or high anticholinergic activity; AC−, participant not taking 
anticholinergic medication; ADD, attention-deficit disorder; ADHD, attention-deficit/ hyperactivity disorder; ADNI, Alzheimer’s Disease 
Neuroimaging Initiative.
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